This Biotech Penny Stock Could Skyrocket 809% Over the Next Year

One of the best sectors to find market-beating gains in 2017 was in the biotech sector, with the SPDR S&P Biotech ETF (NYSE: XBI) returning a market-beating 43.36% in 2017.

In comparison, the S&P 500 climbed 22.5% over the same time period.

And we expect even more market-beating gains in the biotech sector in 2018...

Today, we're going to provide Money Morning readers with all the details about a biotech penny stock that could climb 809% in the next year.

While this isn't a recommendation, we still wanted our readers to be aware of which biotech penny stocks have potentially lucrative price targets from analysts covering them.

Here's everything you need to know about this potential 809% profit opportunity...

This Biotech Penny Stock Could Produce a 809% Windfall

[mmpazkzone name="in-story" network="9794" site="307044" id="137008" type="4"]

Immune Pharmaceuticals Inc. (Nasdaq: IMNP) is a New Jersey-based company developing treatments in the fields of immuno-inflammation and dermatology.

Right now, its "Bertilimumab" drug is in ongoing phase 2 trials for bullous pemphigoid and ulcerative colitis. Phase 2 studies test the efficacy of a drug, and they can last from several months to up to two years.

Bullous pemphigoid is a very rare skin condition with fewer than 20,000 U.S. cases per year, but it's very serious, causing fluid-filled blisters.

Ulcerative colitis is more common, with more than 200,000 U.S. cases per year, and it can cause abdominal cramps and rectal bleeding.

The global ulcerative colitis market is expected to be worth $6.6 billion by 2022, a 57% increase from $4.2 billion in 2012.

Tiny Startup on the Brink of an Epic Sales Surge: With the swing of a gavel, a federal judge just rendered a shocking verdict - and ignited a potential 28,700% revenue surge for a tiny Silicon Valley startup. Go here for all the details - before everyone else gets in on this.

It also has a product in pre-clinical trials called "Nanocyclo."

Nanocyclo aims to patients suffering from psoriasis and atopic dermatitis with an anti-inflammatory remedy.

Psoriasis causes itchy and dry patches on skin and affects more than 3 million people in the United States each year. Atopic dermatitis causes itchy inflammation of the skin and also affects more than 3 million people in the United States each year.

Grand View Research Inc. projects the global psoriasis therapeutics market will be valued at $21.4 billion by 2022, a 386.36% increase from the $4.4 billion U.S. market in 2016.

The global atopic dermatitis market is expected to climb 89.60%, from $4.04 billion in 2016 to $7.66 billion by 2025, according to

And because of these new potential revenue sources, analysts are bullish...

Over the next 12 months, trading and research firm Monness Crespi Hardt projects the IMNP stock price will climb to $3.00 per share.

From today's (Feb. 28) price of $0.33, that's a potential profit of 809%.

Today, we also wanted to share a potentially more lucrative opportunity...

A bitter court battle just ended in a shocking upset, and with a swing of his gavel, a federal judge just ignited an opportunity for a 28,700% sales surge.

This tiny firm is merely a fraction of the size of the biggest blue chips... but the opportunity at hand is part of a market sub-niche responsible for rare trades big enough to turn $1,000 into $1.6 million in a single play.

If you think gains like this could catapult you to millionaire status, start thinking even bigger.

Go here to see how you could claim a spot on the ground floor...

Follow Money Morning on FacebookTwitter, and LinkedIn.